Noncutaneous malignant melanoma: a prognostic model from a retrospective multicenter study

被引:49
作者
Kim, Hyo Song [2 ,6 ]
Kim, Eun Kyoung [1 ]
Jun, Hyun Jung [2 ]
Oh, Sung Yong [3 ]
Park, Keon Woo [4 ]
Lim, Do Hyoung [4 ]
Lee, Soon Il [4 ]
Kim, Jung Han [5 ]
Kim, Kyoung Mee [7 ]
Lee, Dae Ho [1 ]
Lee, Jeeyun [2 ]
机构
[1] Univ Ulsan, Coll Med, Dept Oncol, Asan Med Ctr, Seoul, South Korea
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematooncol,Dept Med, Seoul, South Korea
[3] Dong A Univ, Coll Med, Dong Canc Ctr A, Dept Internal Med, Pusan, South Korea
[4] Dankook Univ, Sch Med, Dept Hematol Oncol, Cheonan, South Korea
[5] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Surg, Seoul, South Korea
[6] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Div Med Oncol, Seoul, South Korea
[7] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol, Seoul, South Korea
关键词
COOPERATIVE-ONCOLOGY-GROUP; POPULATION-BASED INCIDENCE; MUCOSAL MELANOMA; ORAL-CAVITY; CUTANEOUS MELANOMA; MUCOUS-MEMBRANES; KIT; NECK; HEAD; EXPRESSION;
D O I
10.1186/1471-2407-10-167
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: We performed multicenter study to define clinical characteristics of noncutaneous melanomas and to establish prognostic factors patients who received curative resection. Methods: Of the 141 patients who were diagnosed of non-cutaneous melanoma at 4 institutions in Korea between June 1992 and May 2005, 129 (91.5%) satisfied the selection criteria. Results: Of the 129 noncutaneous melanoma patients, 14 patients had ocular melanoma and 115 patients had mucosal melanoma. For mucosal melanoma, anorectum was the most common anatomic site (n = 39, 30.2%) which was followed by nasal cavity (n = 30, 23.3%), genitourinary (n = 21, 16.3%), oral cavity (n = 14, 10.9%), upper gastrointestinal tract (n = 6, 4.7%) and maxillary sinus (n = 5, 3.9%) in the order of frequency. With the median 64.5 (range 4.3-213.0) months follow-up, the median overall survival were 24.4 months (95% CI 13.2-35.5) for all patients, and 34.6 (95% CI 24.5-44.7) months for curatively resected mucosal melanoma patients. Adverse prognostic factors of survival for 87 curatively resected mucosal melanoma patients were complete resection (R1 resection margin), and age > 50 years. For 14 ocular melanoma, Survival outcome was much better than mucosal melanoma with 73.3% of 2 year OS and 51.2 months of median OS (P = .04). Conclusion: Prognosis differed according to primary sites of noncutaneous melanoma. Based on our study, noncutaneous melanoma patients should be treated differently to improve survival outcome.
引用
收藏
页数:8
相关论文
共 37 条
  • [1] L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition
    Antonescu, Cristina R.
    Busam, Klaus J.
    Francone, Todd D.
    Wong, Grace C.
    Guo, Tianhua
    Agaram, Narasimhan P.
    Besmer, Peter
    Jungbluth, Achim
    Gimbel, Mark
    Chen, Chin-Tung
    Veach, Darren
    Clarkson, Bayard D.
    Paty, Philip B.
    Weiser, Martin R.
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2007, 121 (02) : 257 - 264
  • [2] Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma
    Balch, CM
    Buzaid, AC
    Soong, SJ
    Atkins, MB
    Cascinelli, N
    Coit, DG
    Fleming, ID
    Gershenwald, JE
    Houghton, A
    Kirkwood, JM
    McMasters, KM
    Mihm, MF
    Morton, DL
    Reintgen, DS
    Ross, MI
    Sober, A
    Thompson, JA
    Thompson, JF
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) : 3635 - 3648
  • [3] KIT Gene Mutations and Copy Number in Melanoma Subtypes
    Beadling, Carol
    Jacobson-Dunlop, Erick
    Hodi, F. Stephen
    Le, Claudia
    Warrick, Andrea
    Patterson, Janice
    Town, Ajia
    Harlow, Amy
    Cruz, Frank, III
    Azar, Sharl
    Rubin, Brian P.
    Muller, Susan
    West, Rob
    Heinrich, Michael C.
    Corless, Christopher L.
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (21) : 6821 - 6828
  • [4] BERTHELSEN A, 1984, CANCER-AM CANCER SOC, V54, P907, DOI 10.1002/1097-0142(19840901)54:5<907::AID-CNCR2820540526>3.0.CO
  • [5] 2-Z
  • [6] Chang AE, 1998, CANCER, V83, P1664, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO
  • [7] 2-G
  • [8] CHAUDHRY AP, 1958, CANCER-AM CANCER SOC, V11, P923, DOI 10.1002/1097-0142(195809/10)11:5<923::AID-CNCR2820110507>3.0.CO
  • [9] 2-1
  • [10] Phase II trial of combination thalidomide (thal) plus temozolomide (TMZ [TT]), in patients with metastatic malignant melanoma (MMM): Southwest Oncology Group S0508
    Clark, J.
    Moon, J.
    Hutchins, L. F.
    Sosman, J. A.
    Kast, W. M.
    Da Silva, D.
    Liu, P. Y.
    Thompson, J. A.
    Sondak, V. K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)